New developments in HCV therapy
- 10 January 2012
- journal article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 19 (s1), 48-51
- https://doi.org/10.1111/j.1365-2893.2011.01526.x
Abstract
Summary. About half of the patients with chronic hepatitis C are still not cured by treatment with the current standard of care, peginterferon α/ribavirin. Direct antiviral drugs may overcome the limitations of standard antiviral therapy. The most promising new agents are inhibitors of the NS3/4A protease, the NS5B polymerase and the NS5A protein. Several compounds against these targets have entered clinical evaluation. Early clinical trials have emphasized the high potential for selecting resistant Hepatitis C virus variants. Furthermore, development of several new direct antivirals was stopped because of concerns over tolerability and safety. Then, in 2010, two phase III trials with the NS3/4A protease inhibitors boceprevir (SPRINT-2) and telaprevir (ADVANCE) showed that the combination of these compounds with standard care increases sustained virologic response rates in treatment-naïve genotype 1 patients from 38–44% to 66–75%. Future goals of therapy with direct antiviral agents are to improve tolerability, shorten the duration of therapy and overcome the issue of resistance. Several studies have been initiated that combine different novel therapies, with and without interferon α/ribavirin.Keywords
This publication has 10 references indexed in Scilit:
- Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C VirusGastroenterology, 2010
- Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotypeHepatology, 2010
- 57 ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: FINAL RESULTS OF STUDY C209Journal of Hepatology, 2010
- 749 EARLY ON-TREATMENT RESPONSES DURING PEGYLATED IFN PLUS RIBAVIRIN ARE INCREASED FOLLOWING 13 DAYS OF COMBINATION NUCLEOSIDE POLYMERASE (RG7128) AND PROTEASE (RG7227) INHIBITOR THERAPY (INFORM-1)Journal of Hepatology, 2010
- 2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTSJournal of Hepatology, 2010
- Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus InfectionGastroenterology, 2010
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virusNature, 2009
- Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis CNature Genetics, 2009
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 2009
- 10 RESULTS OF A PROOF OF CONCEPT STUDY (C210) OF TELAPREVIR MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 4 HCV PATIENTSJournal of Hepatology, 2009